 Wesley Nuffer
Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Pharmacy | 15 | 2023 | 100 | 4.850 |
Why?
| | Education, Pharmacy | 16 | 2022 | 128 | 4.380 |
Why?
| | Community Pharmacy Services | 9 | 2022 | 45 | 3.840 |
Why?
| | Medication Therapy Management | 4 | 2019 | 67 | 2.260 |
Why?
| | Pharmacies | 5 | 2022 | 32 | 2.050 |
Why?
| | Problem-Based Learning | 4 | 2017 | 77 | 1.520 |
Why?
| | Curriculum | 9 | 2023 | 843 | 1.450 |
Why?
| | Pharmacists | 7 | 2021 | 236 | 1.450 |
Why?
| | Pharmacy | 4 | 2023 | 29 | 1.340 |
Why?
| | Hypoglycemic Agents | 6 | 2022 | 1006 | 1.290 |
Why?
| | Diabetes Mellitus, Type 2 | 7 | 2022 | 2098 | 1.240 |
Why?
| | Anti-Obesity Agents | 3 | 2016 | 45 | 1.130 |
Why?
| | Educational Measurement | 5 | 2020 | 257 | 1.030 |
Why?
| | Pharmaceutical Services | 3 | 2023 | 79 | 0.960 |
Why?
| | Receptors, Glucagon | 2 | 2014 | 23 | 0.950 |
Why?
| | Program Development | 4 | 2017 | 346 | 0.820 |
Why?
| | Liraglutide | 3 | 2016 | 27 | 0.760 |
Why?
| | Glucagon-Like Peptide 1 | 3 | 2015 | 100 | 0.670 |
Why?
| | Models, Educational | 1 | 2018 | 85 | 0.600 |
Why?
| | Perception | 2 | 2017 | 310 | 0.580 |
Why?
| | Blood Glucose | 2 | 2022 | 1821 | 0.520 |
Why?
| | Program Evaluation | 6 | 2020 | 825 | 0.490 |
Why?
| | Drugs, Investigational | 1 | 2014 | 30 | 0.470 |
Why?
| | Rural Health Services | 2 | 2012 | 92 | 0.460 |
Why?
| | Public Health | 2 | 2019 | 435 | 0.440 |
Why?
| | Hypoglycemia | 2 | 2014 | 385 | 0.440 |
Why?
| | Writing | 2 | 2020 | 85 | 0.440 |
Why?
| | Obesity | 2 | 2016 | 2524 | 0.440 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 3 | 2022 | 71 | 0.430 |
Why?
| | Clinical Competence | 2 | 2017 | 899 | 0.420 |
Why?
| | User-Computer Interface | 1 | 2013 | 143 | 0.400 |
Why?
| | Colorado | 7 | 2020 | 4089 | 0.400 |
Why?
| | Hyperglycemia | 1 | 2014 | 293 | 0.380 |
Why?
| | Teaching | 1 | 2013 | 221 | 0.370 |
Why?
| | Humans | 32 | 2023 | 115047 | 0.370 |
Why?
| | Ambulatory Care Facilities | 1 | 2012 | 211 | 0.350 |
Why?
| | Weight Loss | 4 | 2022 | 641 | 0.310 |
Why?
| | Insulin | 2 | 2014 | 2082 | 0.300 |
Why?
| | Preceptorship | 3 | 2019 | 62 | 0.300 |
Why?
| | Patient Care Team | 1 | 2012 | 515 | 0.290 |
Why?
| | Students | 2 | 2023 | 499 | 0.280 |
Why?
| | Diabetes Mellitus | 2 | 2012 | 906 | 0.280 |
Why?
| | Medically Underserved Area | 2 | 2020 | 81 | 0.260 |
Why?
| | Quality Improvement | 2 | 2023 | 953 | 0.240 |
Why?
| | Professional-Patient Relations | 2 | 2018 | 140 | 0.230 |
Why?
| | Cinnamomum zeylanicum | 1 | 2022 | 1 | 0.210 |
Why?
| | Sugars | 1 | 2022 | 29 | 0.210 |
Why?
| | Phytotherapy | 1 | 2022 | 66 | 0.200 |
Why?
| | Body Weight | 2 | 2015 | 873 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2022 | 82 | 0.180 |
Why?
| | Trust | 1 | 2021 | 105 | 0.170 |
Why?
| | Narration | 1 | 2020 | 44 | 0.170 |
Why?
| | Attitude of Health Personnel | 2 | 2020 | 976 | 0.170 |
Why?
| | Cost Savings | 1 | 2019 | 74 | 0.160 |
Why?
| | Professional Role | 2 | 2018 | 152 | 0.160 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3245 | 0.160 |
Why?
| | Private Practice | 1 | 2018 | 20 | 0.160 |
Why?
| | Patient-Centered Care | 2 | 2013 | 474 | 0.160 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2020 | 1184 | 0.150 |
Why?
| | Canagliflozin | 1 | 2017 | 8 | 0.140 |
Why?
| | Glucosides | 1 | 2017 | 36 | 0.140 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 60 | 0.140 |
Why?
| | Patient Care | 1 | 2017 | 103 | 0.130 |
Why?
| | Managed Care Programs | 1 | 2017 | 134 | 0.130 |
Why?
| | Phentermine | 1 | 2016 | 8 | 0.130 |
Why?
| | Rural Population | 1 | 2019 | 446 | 0.130 |
Why?
| | Bupropion | 1 | 2016 | 39 | 0.130 |
Why?
| | Benzazepines | 1 | 2016 | 37 | 0.130 |
Why?
| | Fructose | 1 | 2016 | 100 | 0.130 |
Why?
| | Disease Management | 1 | 2019 | 563 | 0.130 |
Why?
| | Cardiovascular Diseases | 2 | 2017 | 1729 | 0.130 |
Why?
| | Health Occupations | 1 | 2015 | 28 | 0.130 |
Why?
| | Drug Approval | 1 | 2015 | 78 | 0.120 |
Why?
| | Naltrexone | 1 | 2016 | 83 | 0.120 |
Why?
| | Drug Combinations | 1 | 2016 | 287 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 172 | 0.120 |
Why?
| | Medication Adherence | 1 | 2019 | 537 | 0.120 |
Why?
| | Glucagon-Like Peptides | 1 | 2014 | 22 | 0.120 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2014 | 35 | 0.120 |
Why?
| | Injections, Subcutaneous | 1 | 2014 | 133 | 0.120 |
Why?
| | Medicare | 1 | 2019 | 666 | 0.120 |
Why?
| | Cough | 1 | 2014 | 107 | 0.110 |
Why?
| | United States | 3 | 2022 | 12227 | 0.110 |
Why?
| | Chronic Disease | 1 | 2019 | 1591 | 0.110 |
Why?
| | Accountable Care Organizations | 1 | 2013 | 14 | 0.110 |
Why?
| | Academies and Institutes | 1 | 2013 | 44 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2015 | 251 | 0.110 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 476 | 0.110 |
Why?
| | Self Report | 1 | 2017 | 698 | 0.110 |
Why?
| | Administration, Inhalation | 1 | 2014 | 641 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 719 | 0.100 |
Why?
| | Behavior | 1 | 2013 | 91 | 0.100 |
Why?
| | Professional Competence | 1 | 2012 | 84 | 0.100 |
Why?
| | Organizational Objectives | 1 | 2012 | 69 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2014 | 616 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 955 | 0.100 |
Why?
| | Employment | 1 | 2012 | 139 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2019 | 12548 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 185 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1457 | 0.090 |
Why?
| | Life Style | 1 | 2013 | 431 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2015 | 1215 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 937 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2012 | 383 | 0.080 |
Why?
| | Learning | 1 | 2013 | 352 | 0.080 |
Why?
| | Peptides | 1 | 2014 | 849 | 0.080 |
Why?
| | Health Planning Guidelines | 1 | 2009 | 25 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2012 | 682 | 0.070 |
Why?
| | Physician's Role | 1 | 2009 | 199 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2013 | 835 | 0.070 |
Why?
| | Blood Pressure | 1 | 2012 | 1539 | 0.060 |
Why?
| | Qualitative Research | 2 | 2020 | 935 | 0.060 |
Why?
| | Time Factors | 1 | 2013 | 6141 | 0.050 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2022 | 14 | 0.050 |
Why?
| | Biomarkers | 1 | 2012 | 3419 | 0.050 |
Why?
| | Adult | 1 | 2022 | 30658 | 0.050 |
Why?
| | Anecdotes as Topic | 1 | 2020 | 7 | 0.040 |
Why?
| | Competitive Behavior | 1 | 2020 | 40 | 0.040 |
Why?
| | Self Concept | 1 | 2020 | 214 | 0.040 |
Why?
| | Benchmarking | 1 | 2019 | 161 | 0.040 |
Why?
| | Focus Groups | 1 | 2020 | 385 | 0.040 |
Why?
| | Interpersonal Relations | 1 | 2020 | 339 | 0.040 |
Why?
| | Accreditation | 1 | 2017 | 78 | 0.040 |
Why?
| | Emotions | 1 | 2020 | 473 | 0.030 |
Why?
| | Research Report | 1 | 2015 | 75 | 0.030 |
Why?
| | Faculty | 1 | 2015 | 130 | 0.030 |
Why?
| | Schools, Pharmacy | 1 | 2013 | 52 | 0.030 |
Why?
| | Community Networks | 1 | 2013 | 55 | 0.030 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 84 | 0.030 |
Why?
| | Data Collection | 1 | 2012 | 623 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4631 | 0.020 |
Why?
| | Internship and Residency | 1 | 2017 | 941 | 0.020 |
Why?
| | Communication | 1 | 2012 | 744 | 0.020 |
Why?
| | Male | 1 | 2020 | 55735 | 0.010 |
Why?
| | Female | 1 | 2020 | 59617 | 0.010 |
Why?
|
|
Nuffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|